According to a report
published in September of 2014 by Transparency Market Research on anxiety
disorder and depression treatments, the global market for depression treatment
was around $22.5 billion in 2013 and is estimated to be running at around a
1.25% CAGR for the 2014 through 2020 period, after which it will reach some
$18.2 billion. An increase in the availability of generic formulations,
combined with the expiry of patents on such major facets in the market as Eli
Lilly’s (NYSE:LLY) Cymbalta, Pfizer’s (NYSE:PFE) Effexor XR and Actavis’
(NYSE:ACT) Lexapro, is turning increasing attention to a limited number of
newcomers into the market which are on the horizon. Newcomers that are able to
offer compelling advantages over existing SNRI (serotonin-norepinephrine
reuptake inhibitor) and SSRI (selective serotonin reuptake inhibitor)
medications in particular, which have drawn increasing scrutiny in recent years
due to their marginal efficacy and a wide range of potentially serious
complications, like potential life-threatening birth defects in the offspring
of women taking these antidepressants while pregnant, as well as sexual
dysfunction, nausea and insomnia, and risk of suicidal thoughts and behaviors.
Indeed, only about 30% of
depression sufferers respond to first round treatments with SSRI/SNRI
medications and these drugs must be taken for many weeks in most cases before
any noticeable decline in depression is noticed. In the case of MDD (major
depressive disorder), which is characterized as severe, chronic unhappiness, a
condition experienced by some 16 million adults in the U.S. during 2012 alone
(7% of population), an estimated 15% of sufferers ultimately take their own
lives and extant antidepressants have been show to exacerbate problems in many
cases.
This is one major reason
the powerful anaesthesia, sedative and pain reliever, ketamine, despite its
potentially severe side-effects like memory loss, psychosis and liver damage,
has risen to prominence as an MDD treatment following several exploratory
clinical studies at the U.S. National Institutes of Health (NIH). Another major
reason is the distinct pharmacokinetics of ketamine, which has demonstrated
rapid onset antidepressant effects in MDD patients who showed little or no
response to standard antidepressant medications. The clear drawbacks of
ketamine and the obvious risk of abuse, due to the drug having become a popular
street drug because of its hallucinogenic effects, mean that widespread
therapeutic use will likely never occur. However, ketamine’s pharmacokinetics
are quite interesting, because the drug is a potent NMDA (N-methyl-D-aspartate)
receptor antagonist and NMDA channel blocker. Because the NMDA receptor has
been shown to be a key glutamate receptor and ion channel protein in nerve
cells, and because it is now becoming clear how important the glutamatergic
system is to regulating mood and overall neurobiological states in individuals,
substances which can effectively regulate NMDA receptor activity rather than
block it are currently being focused on for development as broad-spectrum
depression treatments.
The market is ripe for a
new generation of real alternatives to SSRIs and SNRIs, agents that can help
treat anxiety, depression and MDD in particular, without the dangerous side
effects and potential for abuse, and that is where VistaGen Therapeutics
(OTCM:VSTA) comes in, with their unique, orally-active prodrug candidate,
AV-101. Because AV-101 is able to efficiently cross the blood-brain barrier, where
it is converted quickly into the extremely well-characterized and highly potent
selective NMDA receptor antagonist 7-Cl-KYNA (7-chlorokynurenic acid), its
fundamentally novel mechanism of action may deliver all the benefits of
ketamine, without the serious side effects.
The NIH funded $8.8
million of VistaGen’s preclinical and Phase 1 clinical development of AV-101.
In two successful NIH-funded AV-101 Phase 1 safety studies, there were no signs
of ketamine’s sedative, hallucinatory or schizophrenia-like side effects. VistaGen
also recently announced in mid-February 2015 that they have subsequently
entered into a cooperative research and development agreement with the NIH’s
National Institute of Mental Health (NIMH) division to collaborate on an
NIH-funded Phase 2 clinical study of AV-101 in MDD. VSTA’s AV-101 is now in a
prime position to emerge as one of the leading candidates in the next wave of
agents in the global antidepressant market. With some 350 million people
worldwide suffering from depression, according to the World Health
Organization’s analysis (as much as 15% of men and 25% of women), there is an
immense underlying demand that goes well beyond the critical MDD market being
validated for AV-101. A novel mechanism of action, safety, rapid onset efficacy
and oral-availability all may spell gold for AV-101.
Learn more by visiting
www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment